Robert Weinstein
CIK 1213709 · Chief Financial Officer · last filed 2026-09-02
Robert Weinstein is a Chief Financial Officer who has filed 38 SEC Form 4 insider transactions across 7 companies since 2008. The most recent filing, for XWEL, was dated Sep 2, 2026. Across all open-market trades the lifetime net is −$197.4K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $210.5K across reported positions. 6 SEC filings were submitted jointly with PharmaCyte Biotech, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
XSPA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 500
LAS VEGAS, NV 89169
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XWEL | Director | 265,231 | $0.56 | $148.6K | $12.4K | 8 | 2026-09-02 |
| PMCB | Director | 41,250 | $0.41 | $16.8K | $0 | 5 | 2026-07-17 |
| TAOX | Chief Financial Officer | 16,574 | $2.72 | $45.1K | $0 | 3 | 2026-05-19 |
| TAO Synergies Inc. (SNPX) Delisted | Chief Financial Officer | 1,328 | $24.55 | $32.6K | -$31.6K | 4 | 2022-12-20 |
| XWELL, Inc. (XSPA) Delisted | Director | 106,485 | $0.66 | $69.7K | -$208.1K | 7 | 2022-04-22 |
| NTRP | See Remarks | 0 | $1.15 | $0 | $0 | 4 | 2020-12-03 |
| Xcorporeal, Inc. (XCR) Delisted | Chief Financial Officer | 20,000 | — | — | $30.0K | 1 | 2008-04-04 |
Recent Filings
38 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-02 | XWEL | Grant (A) | +50,000 | $0 | EDGAR |
| 2026-07-17 | PMCB | Other (J) | — | $0 | EDGAR |
| 2026-05-19 | TAOX | Grant (A) | — | $0 | EDGAR |
| 2026-04-02 | PMCB | Grant (A) | — | $0 | EDGAR |
| 2026-03-02 | XWEL | Grant (A) | +100,000 | $0 | EDGAR |
| 2025-12-12 | PMCB | Mixed | +41,250 | -$34.4K | EDGAR |
| 2025-10-17 | TAOX | Mixed | +6,000 | -$28.9K | EDGAR |
| 2025-07-02 | TAOX | Mixed | +9,246 | -$48.4K | EDGAR |
| 2025-06-03 | XWEL | Grant (A) | +107,407 | $0 | EDGAR |
| 2024-11-18 | XWEL | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.